AR035422A1 - Compuestos derivados de imidazol, un medicamento que contiene uno o mas de dichos compuestos, un proceso para la preparacion de dichos compuestos y uso de dichos compuestos. - Google Patents

Compuestos derivados de imidazol, un medicamento que contiene uno o mas de dichos compuestos, un proceso para la preparacion de dichos compuestos y uso de dichos compuestos.

Info

Publication number
AR035422A1
AR035422A1 ARP020100261A ARP020100261A AR035422A1 AR 035422 A1 AR035422 A1 AR 035422A1 AR P020100261 A ARP020100261 A AR P020100261A AR P020100261 A ARP020100261 A AR P020100261A AR 035422 A1 AR035422 A1 AR 035422A1
Authority
AR
Argentina
Prior art keywords
compounds
lower alkyl
hydrogen
phenyl
amino
Prior art date
Application number
ARP020100261A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Alanine
Bernd Buettelmann
Neidhart Marie Paule Heitz
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR035422A1 publication Critical patent/AR035422A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP020100261A 2001-01-29 2002-01-25 Compuestos derivados de imidazol, un medicamento que contiene uno o mas de dichos compuestos, un proceso para la preparacion de dichos compuestos y uso de dichos compuestos. AR035422A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01101947 2001-01-29

Publications (1)

Publication Number Publication Date
AR035422A1 true AR035422A1 (es) 2004-05-26

Family

ID=8176317

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100261A AR035422A1 (es) 2001-01-29 2002-01-25 Compuestos derivados de imidazol, un medicamento que contiene uno o mas de dichos compuestos, un proceso para la preparacion de dichos compuestos y uso de dichos compuestos.

Country Status (23)

Country Link
US (3) US6610723B2 (cg-RX-API-DMAC7.html)
EP (1) EP1358165B1 (cg-RX-API-DMAC7.html)
JP (1) JP4094956B2 (cg-RX-API-DMAC7.html)
KR (1) KR100619106B1 (cg-RX-API-DMAC7.html)
CN (2) CN101798298B (cg-RX-API-DMAC7.html)
AR (1) AR035422A1 (cg-RX-API-DMAC7.html)
AT (1) ATE425147T1 (cg-RX-API-DMAC7.html)
BR (1) BR0206758A (cg-RX-API-DMAC7.html)
CA (1) CA2434813C (cg-RX-API-DMAC7.html)
CY (1) CY1110265T1 (cg-RX-API-DMAC7.html)
DE (1) DE60231477D1 (cg-RX-API-DMAC7.html)
DK (1) DK1358165T3 (cg-RX-API-DMAC7.html)
ES (1) ES2319967T3 (cg-RX-API-DMAC7.html)
GC (1) GC0000318A (cg-RX-API-DMAC7.html)
GT (1) GT200200013A (cg-RX-API-DMAC7.html)
JO (1) JO2292B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03006773A (cg-RX-API-DMAC7.html)
MY (1) MY138334A (cg-RX-API-DMAC7.html)
PA (1) PA8537801A1 (cg-RX-API-DMAC7.html)
PE (1) PE20020917A1 (cg-RX-API-DMAC7.html)
PT (1) PT1358165E (cg-RX-API-DMAC7.html)
WO (1) WO2002060877A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200305626B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030144B2 (en) * 2002-05-02 2006-04-18 Neurogen Corporation Substituted imidazole derivatives: GABAA receptor ligands
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
US7576221B2 (en) * 2004-06-18 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives
ITRM20050094A1 (it) * 2005-03-04 2006-09-05 Univ Siena Derivati del 1-(1,5-di(4-clorofenil)-2metil-1h-3-pirroli)metil)-4-metilpiperazina (bm 212), procedimento per la loro produzione e uso di essi come antitubercolari.
WO2007042545A1 (en) * 2005-10-14 2007-04-19 Neurosearch A/S Imidazole derivatives and their use for modulating the gaba-a receptor complex
KR100694181B1 (ko) * 2005-11-25 2007-03-12 연세대학교 산학협력단 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법
AU2008256926B2 (en) * 2007-05-23 2013-09-19 Allergan, Inc. ((Bicylicheteroaryl) imidazolyl) methylheteroaryl compounds as adrenergic receptor agonists
WO2010009327A1 (en) * 2008-07-17 2010-01-21 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds for the treatment of pathologies associated with aging and degenerative disorders
NZ601483A (en) 2008-08-04 2013-10-25 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112012018500A2 (pt) 2010-01-25 2016-08-16 Chdi Foundation Inc alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
WO2011101457A1 (en) 2010-02-18 2011-08-25 B.R.A.I.N. Biotechnology Research And Information Network Ag Chimeric surface active proteins
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤
PT2750677T (pt) 2011-08-30 2017-07-03 Chdi Foundation Inc Inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de utilização dos mesmos
WO2013033068A1 (en) 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CA2850508A1 (en) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Imidazole derivatives as cyp17 inhibitors for the treatment of cancer
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
JP2017520610A (ja) 2014-07-17 2017-07-27 シーエイチディーアイ ファウンデーション,インコーポレーテッド Hiv関連障害を治療するための方法及び組成物
DK3180315T3 (da) 2014-08-15 2020-04-06 Janssen Pharmaceuticals Inc Pyrazoler
PL3180329T3 (pl) * 2014-08-15 2020-08-24 Janssen Pharmaceuticals, Inc. Triazole jako inhibitory receptora NR2B
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
KR20180108822A (ko) 2016-02-10 2018-10-04 얀센 파마슈티카 엔.브이. Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
RS63124B1 (sr) 2018-03-08 2022-05-31 Incyte Corp Aminopirazin diol jedinjenja kao pi3k-y inhibitori
MA52244A (fr) 2018-04-04 2021-02-17 Janssen Pharmaceutica Nv Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
KR20220020915A (ko) 2019-06-14 2022-02-21 얀센 파마슈티카 엔.브이. GluN2B 수용체 조절제로서의 피라진 카르바메이트 및 이들의 용도
TW202112774A (zh) 2019-06-14 2021-04-01 比利時商健生藥品公司 經取代之吡唑并-吡啶醯胺及其作為glun2b受體調節劑之用途
PE20220806A1 (es) 2019-06-14 2022-05-20 Janssen Pharmaceutica Nv Pirazolo piridinas heteroaromaticas sustituidas y su uso como moduladores del receptor glun2b
JP2022538774A (ja) 2019-06-14 2022-09-06 ヤンセン ファーマシューティカ エヌ.ベー. ピリジンカルバメート及びglun2b受容体調節因子としてのそれらの使用
EP3983413A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
KR20220020917A (ko) 2019-06-14 2022-02-21 얀센 파마슈티카 엔.브이. 치환된 피라졸로[4,3-b]피리딘 및 GLUN2B 수용체 조절제로서의 이들의 용도
PH12021552839A1 (en) 2019-06-14 2022-10-03 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
CN115656401B (zh) * 2022-11-09 2025-03-28 武汉海特生物创新医药研究有限公司 一种咪唑-4-甲酸乙酯纯度的hplc检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3627155A1 (de) 1986-08-11 1988-02-18 Schering Ag Imidazol-derivate
CN1040107C (zh) * 1993-01-02 1998-10-07 山道士有限公司 咪唑基甲基吡啶
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
IT1300055B1 (it) 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
EP1070708B1 (en) 1999-07-21 2004-01-14 F. Hoffmann-La Roche Ag Triazole derivatives

Also Published As

Publication number Publication date
MY138334A (en) 2009-05-29
MXPA03006773A (es) 2003-10-24
HK1146646A1 (en) 2011-06-24
EP1358165A1 (en) 2003-11-05
PA8537801A1 (es) 2002-09-17
US20020151715A1 (en) 2002-10-17
ES2319967T3 (es) 2009-05-18
CN101798298A (zh) 2010-08-11
US20030191311A1 (en) 2003-10-09
JO2292B1 (en) 2005-09-12
US6683097B2 (en) 2004-01-27
CY1110265T1 (el) 2015-01-14
GC0000318A (en) 2006-11-01
KR20030070615A (ko) 2003-08-30
JP4094956B2 (ja) 2008-06-04
ATE425147T1 (de) 2009-03-15
CA2434813A1 (en) 2002-08-08
CN1489580A (zh) 2004-04-14
US6610723B2 (en) 2003-08-26
US20030187268A1 (en) 2003-10-02
PT1358165E (pt) 2009-04-22
DE60231477D1 (en) 2009-04-23
CA2434813C (en) 2009-12-22
CN101798298B (zh) 2013-01-09
US6667335B2 (en) 2003-12-23
CN1489580B (zh) 2010-05-26
KR100619106B1 (ko) 2006-09-01
ZA200305626B (en) 2004-10-21
BR0206758A (pt) 2004-02-17
HK1063794A1 (en) 2005-01-14
GT200200013A (es) 2002-09-02
PE20020917A1 (es) 2002-10-19
JP2004523535A (ja) 2004-08-05
EP1358165B1 (en) 2009-03-11
DK1358165T3 (da) 2009-05-11
WO2002060877A1 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
AR035422A1 (es) Compuestos derivados de imidazol, un medicamento que contiene uno o mas de dichos compuestos, un proceso para la preparacion de dichos compuestos y uso de dichos compuestos.
RU2515972C2 (ru) Диазакарбазолы и способы применения
AU2015239886B2 (en) Indole derivatives for use in medicine
AU2010286569B2 (en) Compounds and compositions as protein kinase inhibitors
US7091227B2 (en) Benzothiazole derivatives
SG183855A1 (en) Morpholinylquinazolines
RU2014131390A (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ
UY28059A1 (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos.
JP2022191259A (ja) キナーゼネットワークの阻害剤およびその使用
TW200621762A (en) Novel compounds
MX2007003329A (es) Derivados heterociclicos y biciclicos y su uso como inhibidores de estearoil-coa-desaturasa (scd).
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
CZ2002936A3 (cs) Pyrazolopyrimidiny jako terapeutické prostředky
AR002971A1 (es) COMPUESTOS DE 3-(1,2,3,6)-TETRAHIDROPIRIDIN-4-ILO Y 3-PIPERIDIN-4-ILO-1H- INDOL, AGONISTAS DE 5HT(1f) FORMULACIONES FARMACEUTICAS QUE LOS CONTIENEN YMETODOS PARA ACTIVAR DICHOS RECEPTORES 5HT(1f) Y/O PARA TRATAR LAS MIGRANAS Y DESORDENES ASOCIADOS CON ELLA.
NO20061746L (no) Kinazolinderivater som antiproliferative midler
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
SG172805A1 (en) Amino-heterocyclic compounds used as pde9 inhibitors
CZ20032858A3 (en) Pyrazolopyrimidines as therapeutic agents
UY28578A1 (es) Derivados de amida
EP3215155A1 (en) Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
TW200829588A (en) Imidazopyrazines as protein kinase inhibitors
US8895729B2 (en) Process for making thienopyrimidine compounds
UY27592A1 (es) Nuevo uso
MXPA05001585A (es) Nuevo uso de derivados de benzotiazol.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee